News | December 12, 2024
Biocon Biologics recognized as Asia IP Elite for 2024 by IAM
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
Biocon Biologics is among the two pharmaceutical companies from India in the 93 companies featuring on the Asia IP Elite 2024 list
The first and only immuno-oncology drug approved for the treatment of nasopharyngeal carcinoma
Roger Dansey to become Interim Chief Oncology Officer and Johanna Bendell to join Pfizer as Oncology Chief Development Officer
Revenue at Rs 3,623 crore, EBITDA at Rs 718 crore
The market size of Aspart in India is currently estimated over Rs. 260 crore with only 2 players
We now rank 3rd in pharmaceutical production by volume and 14th by value
DKSH has entered into an exclusive partnership with R-Biomeds to bring the necessary medication to patients in Cambodia
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
The Notes shall not be offered or sold in India
Biocon Biologics earlier announced a settlement agreement in the United States for a Bmab 1200 launch no later than February 22, 2025
Subscribe To Our Newsletter & Stay Updated
